An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
Public ClinicalTrials.gov record NCT01116245. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Cervical cancer is associated with Human Papilloma Virus. About 57% of cervical cancer is the result of infection by Human Papilloma Virus strain 16 (HPV-16). HPV is a very common virus that can affect the cells of the cervix. E7 is a substance that is made by the HPV virus which causes cervical cancer. The purpose of the study is to test the safety, tolerability (how the drug makes you feel), immunology (effects on the immune system) and efficacy (disease curing effects) of a vaccine called Lovaxin C against E7. The vaccine is designed to cause the immune system to react against the E7 substance in a manner that is intended to reverse the changes to the cervix and prevent cervical cancer from occurring.
Study identification
- NCT ID
- NCT01116245
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 81 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 45 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2010
- Primary completion
- Nov 30, 2013
- Completion
- Mar 31, 2016
- Last update posted
- Jul 26, 2016
2010 – 2016
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| New Horizons Women's Care, LLC | Chandler | Arizona | 85224 | — |
| Arizona OB/GYN Affiliates, PC | Phoenix | Arizona | 85016 | — |
| Precision Trials | Phoenix | Arizona | 85032 | — |
| Visions Clinical Research - Tucson | Tucson | Arizona | 85712 | — |
| Grossmont Center for Clinical Research | La Mesa | California | 91942 | — |
| Visions Clinical Research | Boynton Beach | Florida | 33472 | — |
| Altus Research | Lake Worth | Florida | 33461 | — |
| Center for Women | Chicago | Illinois | 60612 | — |
| Indiana University Dept. of OB/GYN Oncology | Indianapolis | Indiana | 46202 | — |
| New York Downtown Hospital | New York | New York | 10038 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Temple University | Philadelphia | Pennsylvania | 19140 | — |
| InVisions Consultants, LLC- c/o Institute for Women's Health | San Antonio | Texas | 78212 | — |
| InVisions Consultants, LLC | San Antonio | Texas | 78217 | — |
| Wasatch Clinical Research | Salt Lake City | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01116245, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2016 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01116245 live on ClinicalTrials.gov.